Similar articles for PMID: 20564061

Year	Number of Results
1998	1
1999	1
2000	1
2001	1
2003	2
2004	2
2006	2
2007	7
2008	8
2009	8
2010	6
2011	8
2012	10
2013	9
2014	15
2015	6
2016	16
2017	19
2018	16
2019	14
2020	23
2021	20
2022	15
2023	8
2024	0

1

Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?

Culp SH, Tannir NM, Abel EJ, Margulis V, Tamboli P, Matin SF, Wood CG. Culp SH, et al. Cancer. 2010 Jul 15;116(14):3378-88. doi: 10.1002/cncr.25046. Cancer. 2010. PMID: 20564061 Free article.

2

Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood LA, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Kim JJ, Choueiri TK. Heng DY, et al. Eur Urol. 2014 Oct;66(4):704-10. doi: 10.1016/j.eururo.2014.05.034. Epub 2014 Jun 13. Eur Urol. 2014. PMID: 24931622

3

Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.

Mathieu R, Pignot G, Ingles A, Crepel M, Bigot P, Bernhard JC, Joly F, Guy L, Ravaud A, Azzouzi AR, Gravis G, Chevreau C, Zini L, Lang H, Pfister C, Lechevallier E, Fais PO, Berger J, Vayleux B, Roupret M, Audenet F, Descazeaud A, Rigaud J, Machiels JP, Staehler M, Salomon L, Ferriere JM, Kleinclauss F, Bensalah K, Patard JJ. Mathieu R, et al. Urol Oncol. 2015 Aug;33(8):339.e9-15. doi: 10.1016/j.urolonc.2015.05.014. Epub 2015 Jun 16. Urol Oncol. 2015. PMID: 26087971

4

Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy.

McIntosh AG, Umbreit EC, Holland LC, Gu C, Tannir NM, Matin SF, Karam JA, Culp SH, Wood CG. McIntosh AG, et al. Cancer. 2020 Sep 1;126(17):3950-3960. doi: 10.1002/cncr.32991. Epub 2020 Jun 9. Cancer. 2020. PMID: 32515845 Free article. Clinical Trial.

5

Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.

Sharma P, Zargar-Shoshtari K, Caracciolo JT, Fishman M, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE. Sharma P, et al. Urol Oncol. 2015 Aug;33(8):339.e17-23. doi: 10.1016/j.urolonc.2015.01.011. Epub 2015 Jun 18. Urol Oncol. 2015. PMID: 26094169

6

The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.

Claeys T, Lumen N, Kumps C, Praet M, De Meerleer G, Rottey S, Ost P, Devisschere P, Villeirs G, Fonteyne V, Decaestecker K. Claeys T, et al. Urol Oncol. 2017 Apr;35(4):152.e13-152.e22. doi: 10.1016/j.urolonc.2016.10.013. Epub 2017 Jan 30. Urol Oncol. 2017. PMID: 28153420

7

Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy.

Song Y, Du CX, Zhang W, Sun YK, Yang L, Cui CX, Chi YB, Shou JZ, Zhou AP, Li CL, Ma JH, Wang JW, Sun Y. Song Y, et al. Chin Med J (Engl). 2016 Mar 5;129(5):530-5. doi: 10.4103/0366-6999.177001. Chin Med J (Engl). 2016. PMID: 26904986 Free PMC article.

8

Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.

Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S, Karam JA, Mason RJ, Powles T, Bex A. Bhindi B, et al. Eur Urol. 2019 Jan;75(1):111-128. doi: 10.1016/j.eururo.2018.09.016. Epub 2018 Oct 25. Eur Urol. 2019. PMID: 30467042

9

Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.

Fukuda H, Takagi T, Kondo T, Yoshida K, Shimizu S, Nagashima Y, Tanabe K. Fukuda H, et al. Int J Clin Oncol. 2018 Jun;23(3):539-546. doi: 10.1007/s10147-017-1221-z. Epub 2018 Jan 5. Int J Clin Oncol. 2018. PMID: 29302841

10

Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era.

Culp SH, Karam JA, Wood CG. Culp SH, et al. Urol Oncol. 2014 Jul;32(5):561-8. doi: 10.1016/j.urolonc.2013.12.003. Epub 2014 Apr 4. Urol Oncol. 2014. PMID: 24709415

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

177 results

Results by year